Novartis targets undruggable cancers with $1.9bn Antares Therapeutics deal
Antares’ lead precision oncology programme is expected to enter the clinic in 2026.
Featured s
ŌURA and Lilly join forces to harmonise drug-wearable obesity care
This partnership marks another addition to the growing list of high-profile collaborations between the consumer health and life science sectors.
All Articles
Novartis targets undruggable cancers with $1.9bn Antares Therapeutics deal
Antares’ lead precision oncology programme is expected to enter the clinic in 2026.
ŌURA and Lilly join forces to harmonise drug-wearable obesity care
This partnership marks another addition to the growing list of high-profile collaborations between the consumer health and life science sectors.
Boehringer and Combotope partner for cancer antibodies
Combotope will deploy its platform to discover antibodies, accompanied by a specific antibody characterisation data package.
Haisco and Nuvectis sign licensing deal for two drugs
Haisco will receive $40m upfront and may earn up to $1.4bn in additional milestone payments.
BIO 2026: NVIDIA announces the BioNeMo toolkit for AI agents
The suite of tools is designed to allow AI to carry out R&D work more quickly, reliably, and in a…
Early Biomarkers as Predictors of Nephrology Trial Trajectory
Faced with slow-moving study endpoints and distant clinical thresholds, nephrology sponsors need earlier, actionable insights to support critical development decisions…
From collection to confidence: why clinical trial data reliability starts early
In early-phase research, reliable data can determine whether a programme advances, stalls or stops. Sponsors need quality signals they can…
BIO 2026: Cell and gene therapy firms outline their use of AI in manufacturing
From data lakes to streamlined production, Kriya, Opus, and Epicrispr discuss how technology is improving their operations.
FDA changes rare disease tune again as it clears path for Regenxbio’s gene therapy
With a regulatory route now in place, Regenxbio expects to meet with the FDA again in July, with a BLA…
Genprex’s Reqorsa combo secures Canadian patent for lung cancer
Reqorsa is currently in development alongside approved cancer drugs.